Translate Bio provided an update on its lead clinical candidate, MRT5005, currently in development for the treatment of cystic fibrosis, and on its second product candidate, MRT5201, in development for the treatment of ornithine transcarbamylase deficiency.The initiation of the multiple-dose portion of the Phase 1/2 clinical trial of MRT5005 is an important milestone as it represents the first time that multiple doses of an mRNA therapeutic have been given to patients for the treatment of a genetic disease,” said Ronald Renaud, chief executive officer, Translate Bio. “We look forward to expanding our knowledge of the safety profile of MRT5005 with multiple doses and believe that this progress underscores its potential to make an impact in the treatment of patients with cystic fibrosis.”
https://thefly.com/landingPageNews.php?id=2871693
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.